TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05996991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive expectation speech regarding spinal manipulative therapy
Description: Patients will watch a short video with positive expectations regarding spinal manipulative therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral expectation speech regarding spinal manipulative therapy
Description: Patients will watch a short video with neutral expectations regarding spinal manipulative therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative expectation speech regarding spinal manipulative therapy
Description: Patients will watch a short video with negative expectations regarding spinal manipulative therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy
Description: One session of Spinal Manipulative Therapy. The researcher will administer a posterior and inferior push on the opposite anterior superior iliac spine (ASIS) while passively rotating the subject on the side to be manipulated. The spinal manipulations will be repeated four times during a 5-minute period, with impulses oscillating between the right and left ASIS. In addition, we will administrate mobilizations (anterior-posterior central mobilization), applied for 1 minute in each lumbar vertebra (from L5 to L1), using grade I joint mobilization (patients positioned in the ventral decubitus position).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulative Therapy
Description: One session of Spinal Manipulative Therapy. The researcher will administer a posterior and inferior push on the opposite anterior superior iliac spine (ASIS) while passively rotating the subject on the side to be manipulated. The spinal manipulations will be repeated four times during a 5-minute period, with impulses oscillating between the right and left ASIS. In addition, we will administrate mobilizations (anterior-posterior central mobilization), applied for 1 minute in each lumbar vertebra (from L5 to L1), using grade I joint mobilization (patients positioned in the ventral decubitus position).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulative Therapy
Description: One session of Spinal Manipulative Therapy. The researcher will administer a posterior and inferior push on the opposite anterior superior iliac spine (ASIS) while passively rotating the subject on the side to be manipulated. The spinal manipulations will be repeated four times during a 5-minute period, with impulses oscillating between the right and left ASIS. In addition, we will administrate mobilizations (anterior-posterior central mobilization), applied for 1 minute in each lumbar vertebra (from L5 to L1), using grade I joint mobilization (patients positioned in the ventral decubitus position).
Study: NCT05201456

Intervention type: DEVICE
Intervention: LithoVue Elite System
Description: The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.

Intervention type: DEVICE
Intervention: LithoVue Elite System
Description: The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
Study: NCT04482023

Intervention type: BEHAVIORAL
Intervention: Training video on anxiety, fear and loneliness in the COVID-19 environment.
Description: Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
Study: NCT04853875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline, Metronidazole, Bismuth subcitrate
Description: 52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin, Metronidazole, Clarithromycin
Description: 52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
Study: NCT05112120

Intervention type: DRUG
Intervention: Olumiant
Description: Olumiant (4mg) will be administered in line with standard of care guidance.
Study: NCT05866250

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler-based renal resistive index
Description: The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
Study: NCT06255847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide, cyclophosphamide combined with dexametha
Description: The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
Study: NCT05752422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Niraxx G1 Headband Device including sham
Description: Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Niraxx G1 Headband Device including sham
Description: Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
Study: NCT05059353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digitally based multidomain intervention
Description: Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed.
Study: NCT05399771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler
Description: Study team will use a PeriScan PIM 3 System Laser Doppler to scan for blood perfusion before and after the Thermofield treatment. The PeriScan PIM 3 System is for non-invasive two-dimensional imaging of peripheral tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Heating System
Description: The radiofrequency will be set to achieve 42°C/107.6°F) and maintain this temperature consistently during the application time. This temperature is mild and may feel like a drugstore heating pad. The device will be turned on on one leg and will remain off on the other. The time for the heating will be 36 minutes, during which participants will remain in a reclined position, with their legs elevated. The device takes approximately 6 minutes to achieve a tissue temperature of 42°C, and the treatment time with consistent temperature application will be 30 minutes.
Study: NCT04840030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (MM-int)
Description: 1. Cognitive intervention objective: To enhance cognitive functioning and incorporate daily habits and routines that are cognitively stimulating~2. Socio-emotional intervention objective: • Promote socio-emotional skills associated with awareness, communication and regulation of emotions in late life.~3. Nutritional intervention objective: To improve eating habits of participants to be based on the Mediterranean Dietary pattern by an educational program~4. Physical activity intervention objective: To improve aerobic capacity y, decrease the risk of falls, and improve static and dynamic balance.~5. Risk factors and comorbidities monitoring intervention: quarterly scheduled visits for a cardiovascular risk factors check-up and review active medication
Study: NCT05576974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegsitacianine
Description: Infusion of the Pegsitacianine-Intraoperative fluorescence imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegsitacianine
Description: Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
Study: NCT05795478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone and Pregabalin
Description: Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1\~7,75mg QD for POD8\~14

Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone and placebo capsules
Description: Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin and NS
Description: Pregabalin: 150mg preoperatively, 75mg BID for POD1\~7,75mg QD for POD8\~14 NS: Equal volume NS for 3 days postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules and NS
Description: placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
Study: NCT05146453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectointercostal fascia blocks
Description: PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
Study: NCT05291468

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET/CT
Description: Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET/CT
Description: Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: FDG-PET/CT
Description: Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: FDG-PET/CT
Description: Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
Study: NCT05944978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-035
Description: GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
Study: NCT06255366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caroxime sodium sulfonate
Description: Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
Study: NCT05098275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/500mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/500mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/500mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/500mg
Description: single dose administration (one tablet once a day)
Study: NCT06408155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Task
Description: The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Task
Description: The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Task
Description: The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Task
Description: The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.
Study: NCT05449470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDSS
Description: A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Portal
Description: A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
Study: NCT04804215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraductal transanastomotic stent group
Description: When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No stent group
Description: Do not insert a stent into the bile duct during anastomosis of the bile duct.
Study: NCT05399771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Imaging
Description: Study team will take thermal imaging photographs of the treatment area following each treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthcare Questionnaire & Measurement
Description: A survey tool created to collect info from participants including:~1. Name~2. Age~3. Weight/ height~4. Pregnant or nursing?~5. History of blood clots?~6. Any wound healing problems?~7. Any active open wounds on the legs?~8. Any autoimmune disorders?~9. Phone number~10. Email address~A measurement of the participants calf will be taken as well using a measuring tape.
Study: NCT05579340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 months of combined aerobic and resistance exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 months of combined aerobic and resistance exercise
Study: NCT06488391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using a Portable Visualized Device for Self-Directed Breathing Training
Description: Using a Portable Visualized Device for Self-Directed Breathing Training
Study: NCT06022718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: Kinesio taping and Rigid taping was applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: Kinesio taping and Rigid taping was applied.
Study: NCT04926415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham taVNS
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham taVNS
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham taVNS
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
Study: NCT03994159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the PARO emotional robot
Description: PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
Study: NCT05834855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment with rituximab
Study: NCT04307875

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure measurement (sphygmomanometer)
Description: measuring blood pressure with standard sphygmomanometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure measurement (sphygmomanometer)
Description: measuring blood pressure with standard sphygmomanometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood glucose measurement
Description: measuring blood glucose using standard measurement devices

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood glucose measurement
Description: measuring blood glucose using standard measurement devices

Intervention type: OTHER
Intervention: psychometric tests
Description: WHODAS 2.0, PHQ-9, CAPS-5

Intervention type: OTHER
Intervention: psychometric tests
Description: WHODAS 2.0, PHQ-9, CAPS-5